Literature DB >> 19587659

More eyeballs on AERS.

Leslie A Pratt, Paul N Danese.   

Abstract

Mesh：

Year:  2009        PMID： 19587659     DOI： 10.1038/nbt0709-601

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.

Authors:  June S Almenoff; Karol K LaCroix; Nancy A Yuen; David Fram; William DuMouchel
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Making a difference.

Authors: 
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

3.  Withdrawal of cerivastatin from the world market.

Authors:  Curt D Furberg; Bertram Pitt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001
  3 in total
  4 in total

1.  OpenVigil--free eyeballs on AERS pharmacovigilance data.

Authors:  Ruwen Böhm; Jan Höcker; Ingolf Cascorbi; Thomas Herdegen
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

2.  Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.

Authors:  H Fang; Z Su; Y Wang; A Miller; Z Liu; P C Howard; W Tong; S M Lin
Journal:  Clin Pharmacol Ther       Date:  2014-01-21       Impact factor: 6.875

Review 3.  Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.

Authors:  June M McKoy; Matthew J Fisher; D Mark Courtney; Dennis W Raisch; Beatrice J Edwards; Marc H Scheetz; Steven M Belknap; Steven M Trifilio; Athena T Samaras; Dustin B Liebling; Beatrice Nardone; Katrina Marie Tulas; Dennis P West
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

Review 4.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.